<p>(A) The mean (95% CI) change from baseline to 3 months in HFI (μS s-1) between the placebo and treatment groups. (B) The mean (95% CI) change from baseline to 3 months in 24hr HFF (total number of peaks) in the placebo and treatment groups. In all figures the Placebo group are marked as blue and RCE as red and significance is denoted as:* P<0.05, ** P<0.01.</p
<p>N = 16. Values are means (SD).</p>§<p>Data was log<sub>10</sub> transformed before analysis.</p><...
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>(A) Proportion of patients with ≥1 point reduction in PFS (primary endpoint). (B) Improvement of ...
<p>(A) Summarized data for mean LF/HF at baseline, 240 days and 720 days after AC. Mean LF/HF is ave...
<p>(A) Left: The mean HOMA-IR decreased somewhat in both groups between the baseline and after treat...
<p>Baseline and 6 month data are presented as mean (SD).</p><p>*A multivariate 2-factor repeated-mea...
<p>Baseline data are presented as mean (SD).</p><p>*A multivariate 2-factor repeated-measures regres...
<p>Change in microfilarial density in the treatment groups at different follow up points: Mean (SD) ...
<p>Both HF (Fig. 6A) and LF/HF (Fig. 6B) were not significantly different between the two groups dur...
<p>Change baseline-12 months (Δ) for selected parameters. Values are given as means with 95% confide...
<p>Open circles, ghrelin; closed circles, placebo. Data are presented as mean differences±SE. * p<0....
Average RTs in placebo and ACh group (grey) for one example block from each of the three types and a...
<p>Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before a...
<p>Mean values are shown for percentage changes from baseline of A) FBG, B) PBG, C) body weight and ...
<p>Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein)</p><p>*P-value for i...
<p>N = 16. Values are means (SD).</p>§<p>Data was log<sub>10</sub> transformed before analysis.</p><...
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>(A) Proportion of patients with ≥1 point reduction in PFS (primary endpoint). (B) Improvement of ...
<p>(A) Summarized data for mean LF/HF at baseline, 240 days and 720 days after AC. Mean LF/HF is ave...
<p>(A) Left: The mean HOMA-IR decreased somewhat in both groups between the baseline and after treat...
<p>Baseline and 6 month data are presented as mean (SD).</p><p>*A multivariate 2-factor repeated-mea...
<p>Baseline data are presented as mean (SD).</p><p>*A multivariate 2-factor repeated-measures regres...
<p>Change in microfilarial density in the treatment groups at different follow up points: Mean (SD) ...
<p>Both HF (Fig. 6A) and LF/HF (Fig. 6B) were not significantly different between the two groups dur...
<p>Change baseline-12 months (Δ) for selected parameters. Values are given as means with 95% confide...
<p>Open circles, ghrelin; closed circles, placebo. Data are presented as mean differences±SE. * p<0....
Average RTs in placebo and ACh group (grey) for one example block from each of the three types and a...
<p>Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before a...
<p>Mean values are shown for percentage changes from baseline of A) FBG, B) PBG, C) body weight and ...
<p>Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein)</p><p>*P-value for i...
<p>N = 16. Values are means (SD).</p>§<p>Data was log<sub>10</sub> transformed before analysis.</p><...
(A) according to lipid-lowering and antiplatelet drugs; (B) for combined therapies. Simvastatin/ezet...
<p>(A) Proportion of patients with ≥1 point reduction in PFS (primary endpoint). (B) Improvement of ...